Flashpoint Therapeutics announces $50M Partnership with KAIMRC and Clinical Pipeline Expansion
Acquiring Company
Flashpoint Therapeutics
Acquired Company
The King Abdullah International Medical Research Center (KAIMRC)
Chicago
RiyadhBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareMedicalDescription
Flashpoint Therapeutics, a clinical-stage therapeutics company, has announced a significant expansion of its therapeutic pipeline through strategic acquisitions and a new $50M partnership with The King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia. The partnership establishes the state-of-the-art Flashpoint-KAIMRC Center of Excellence (COE) in Structural Nanomedicine, which is expected to receive significant funding to conduct clinical trials on structural nanomedicine candidates and advance drug discovery programs targeting prevalent diseases.
Quick answer
Flashpoint Therapeutics is acquiring The King Abdullah International Medical Research Center (KAIMRC), announced November 14, 2024. Flashpoint Therapeutics is based in Chicago, Illinois, United States.
- How much did Flashpoint Therapeutics pay for The King Abdullah International Medical Research Center (KAIMRC)?
- The deal value was not disclosed.
- What does Flashpoint Therapeutics do?
- Flashpoint Therapeutics is at the forefront of drug discovery with its innovative structural nanomedicine platform.
- Where are Flashpoint Therapeutics and The King Abdullah International Medical Research Center (KAIMRC) based?
- Flashpoint Therapeutics is based in Chicago, Illinois, United States. The King Abdullah International Medical Research Center (KAIMRC) is based in Riyadh, Riyadh Region, Saudi Arabia.
- Who are the decision-makers at Flashpoint Therapeutics?
- Fundz holds 3 contacts at Flashpoint Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- Organon successfully acquires Dermavant Sciences Ltd. to expand dermatology portfolio (October 28, 2024)
- OraSure Technologies completes acquisition of Sherlock Biosciences, Inc. to expand its innovation pipeline in molecular testing market (December 19, 2024)
- Medtronic completes acquisition of Fortimedix to enhance its surgical technology portfolio (November 22, 2024)
- Novartis acquires Kate Therapeutics to strengthen gene therapy portfolio (November 21, 2024)
- Trinity Biotech plc acquires EpiCapture Limited to expand into oncology diagnostics (October 25, 2024)
Who to call at Flashpoint Therapeutics, and when
When Flashpoint Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Flashpoint Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Flashpoint Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Flashpoint Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Flashpoint Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired The King Abdullah International Medical Research Center (KAIMRC)?
The King Abdullah International Medical Research Center (KAIMRC) was acquired by Flashpoint Therapeutics, based in Chicago. The deal was reported on November 14, 2024. Flashpoint Therapeutics is at the forefront of drug discovery with its innovative structural nanomedicine platform. Flashpoint Therapeutics is privately held and operates in Biotechnology.
When did Flashpoint Therapeutics acquire The King Abdullah International Medical Research Center (KAIMRC)?
Flashpoint Therapeutics's acquisition of The King Abdullah International Medical Research Center (KAIMRC) was reported on November 14, 2024. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does The King Abdullah International Medical Research Center (KAIMRC) do?
The King Abdullah International Medical Research Center (KAIMRC) is a research center committed to advancing medical research and bringing innovative therapeutic approaches to address complex diseases. It is privately held, operating in Biotechnology, and is based in Riyadh.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.